<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01269437</url>
  </required_header>
  <id_info>
    <org_study_id>NM2010002</org_study_id>
    <nct_id>NCT01269437</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Budesonide Novolizer Dry Powder Inhaler 200μg to Treat Chinese Patients With Mild to Moderate Asthma</brief_title>
  <official_title>Open-label, Randomized, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Budesonide Novolizer Dry Powder Inhaler Compared With Budesonide Turbuhaler Dry Powder Inhaler in Chinese Mild to Moderate Asthma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovaMed Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NovaMed Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomized, parallel Group, multicenter study to evaluate the efficacy
      and safety of budesonide novolizer dry powder inhaler compared with budesonide turbuhaler dry
      powder inhaler in Chinese mild to moderate asthma patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">October 2011</completion_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate the non-inferiority of budesonide delivered by Novolizer to that delivered by Turbuhaler in terms of mPEF （morning peak expiratory flow） in Chinese mild to moderate asthma patients</measure>
    <time_frame>12 weeks</time_frame>
    <description>The change of mPEF in the Week 11-12 of treatment from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the improvement of FEV1(Forced Expiratory Volume in One Second) in Chinese mild to moderate asthma patients after treatment of budesonide delivered by Novolizer or Turbuhaler</measure>
    <time_frame>12 weeks</time_frame>
    <description>The change of FEV1 in the Week 12 of treatment from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the improvement of ePEF （Evening Peak Expiratory Flow） in Chinese mild to moderate asthma patients after treatment of budesonide delivered by Novolizer or Turbuhaler</measure>
    <time_frame>12 weeks</time_frame>
    <description>The change of ePEF in the Week 11-12 of treatment from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the improvement in ACT (Asthma Control Test) score in Chinese mild to moderate asthma patients after treatment of budesonide delivered by Novolizer or Turbuhaler</measure>
    <time_frame>12 weeks</time_frame>
    <description>The change of ACT scores in the Week 12 of treatment from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the tolerability and safety of budesonide delivered by Novolizer or Turbuhaler in Chinese mild to moderate asthma patients</measure>
    <time_frame>15 weeks</time_frame>
    <description>It will be assessed according to numbers of adverse event and laboratory results</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">332</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Budesonide, Novolizer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide Dry Powder Inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BudesonideTurbuhaler</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Budesonide Dry Powder Inhaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide dry powder inhaler</intervention_name>
    <description>200mcg per inhalation, twice daily, for 12 weeks</description>
    <arm_group_label>Budesonide, Novolizer</arm_group_label>
    <arm_group_label>BudesonideTurbuhaler</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent by the subject and his/her legal guardian if the subject
             is under 18 years old.

          -  Male or females aged more than 12 and under 70

          -  Had a definite diagnosis of asthma with symptoms of cough/expectoration/chest
             tightness/wheeze/breathlessness within the last one month

          -  Inhaled corticosteroid (ICS) naïve or no regular use of ICS within the last one month
             (It is suggested that ICS average daily dose with no more than 100mg budesonide or
             equal within the last month as &quot;No-regular-use&quot;)

          -  FEV1 between 60% and 85% of predicted normal values

          -  Reversibility test of airway obstruction is positive, i.e. degree of reversibility in
             FEV1 as over 12%(included) and 200ml(included). Or average diurnal PEFR variability is
             not less than 20% in two weeks.

          -  Are able to use Peak Flow Meter and record it on patient diary card

        Exclusion Criteria:

          -  Asthma exacerbation leading to hospitalization for more than 2 days within the last 6
             months or emergency room visit due to asthma exacerbation in the last 3 months prior
             to screening

          -  Infection of respiratory system in the last 4 weeks prior to screening visit

          -  Use of oral, injectable, rectal or transdermal glucocorticoid in the last 4 weeks
             prior to screening visit

          -  Use of Leukotriene receptor antagonist (LTRAs), oral b2 agonist, methylxanthines or
             use of inhaled long acting b2 agonist, inhaled anticholinergic receptor in the last 1
             week, or inhaled Tiotropium Bromide within 45 days prior to screening visit

          -  Patients with chronic obstructive pulmonary disease (COPD)or COPD with asthma

          -  Patients with severe persistent asthma (Based on definition in GINA 2006)

          -  Patients with specific immunity treatment (including monoclonal antibody treatment)
             due to asthma within the 6 months prior to screening visit

          -  Patients with eye disorders including cataract, glaucoma and herpes virus infection

          -  Smoking history of 10 pack-year (1 pack-year refers to 20 cigarette per day for 1
             year)

          -  History of drug or alcohol abuse

          -  History of adrenal disease

          -  History of malignancy disease in the last 5 years, with the exception of basal cell
             carcinoma

          -  Heart function failure or any severe systematic disease, at the investigator's
             discretion, which will make it undesirable for the patient to participate in the trial
             or which could jeopardize compliance with the trial protocol

          -  ALT or AST &gt; 2 times of upper limit of reference range

          -  Creatinine (Cr) &gt; 159µmol/L for males or &gt; 141µmol/L for females

          -  Patients with hypersensitivity to budesonide and/or lactose

          -  Participation in a clinical study or treatment with a non-approved experimental
             medication in the last 1 month

          -  Pregnant or breast-feeding women, or women of childbearing age without appropriate
             contraception measures

        Limitations:

        The following medications are prohibited from screening onward:

          -  Use of oral, injectable, rectal or transdermal glucocorticoid

          -  Inhaled nedocromil sodium/Inhaled cromoglycate sodium

          -  Leukotriene receptor antagonist

          -  Methylxanthines

          -  Inhaled long acting b2 agonist

          -  Oral b2 agonist

          -  Inhaled anticholinergic receptor

          -  Any b2 receptor blocker (Including eye drops)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunxue BAI, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Second Artillery General Hospital of PLA</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suiyang ZHANG</last_name>
      <phone>+86 13693652527</phone>
      <email>suiyangzhang@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ai'E WANG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suiyang ZHANG</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kaicheng MEI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hong ZHANG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jianxin MA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chuanlian YAN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dongxia WANG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chaoxia LI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ying WANG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Foshan</name>
      <address>
        <city>Foshan</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiyang LUO</last_name>
      <phone>+86 13929930368</phone>
      <email>zhiyangluo@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Zhiyang LUO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gang CHEN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yueming LIANG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jian LIU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shaozhi HU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peifang ZHANG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yanhua FAN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangzhou First Municipal People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ziwen ZHAO, Professor</last_name>
      <phone>+86 13006872260</phone>
      <email>zhaozw@yeah.net</email>
    </contact>
    <investigator>
      <last_name>Ziwen ZHAO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shuquan WEI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaoyan LI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhigao XIA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical College, Guangzhou Institute of Respiratory Disease</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kefang LAI, Professor</last_name>
      <phone>+86 13719138526</phone>
      <email>klai@163.com</email>
    </contact>
    <investigator>
      <last_name>Kefang LAI</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Siqi JIANG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xu ZHANG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Baojuan LIU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital of Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong LIN, Professor</last_name>
      <phone>+86 13951899504</phone>
      <email>linyong63@163.com</email>
    </contact>
    <investigator>
      <last_name>Yong LIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qiang ZHANG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Weilan LI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li ZHAO</last_name>
      <phone>+86 024 96615-21121</phone>
      <email>zhaol@sj-hospital.org</email>
    </contact>
    <investigator>
      <last_name>Yu LI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaoman XU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cuihong WANG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li ZHAO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lihua ZHU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heng DAI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dongfang Hospital Affiliated to Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongjie LIANG</last_name>
      <phone>+86 21 38804518</phone>
      <phone_ext>6191</phone_ext>
    </contact>
    <investigator>
      <last_name>Yongjie LIANG</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qi YIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Putuo District Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiongbiao WANG</last_name>
      <phone>+86 021 62572723</phone>
      <email>xiongbiao6@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Xiongbiao WANG</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunxue BAI</last_name>
      <phone>+86 13681971807</phone>
      <email>bai.chunxue@zs-hospital.sh.cn</email>
    </contact>
    <investigator>
      <last_name>Chunxue BAI, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meiling JIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dong YANG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maosong YE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ling YE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qi CHEN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xia AN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The General Hospital of Shenyang Military Region</name>
      <address>
        <city>Shenyang</city>
        <state>Shenyang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping CHEN, Professor</last_name>
      <phone>+86 13309887193</phone>
      <email>cp59620@sina.com</email>
    </contact>
    <investigator>
      <last_name>Haitao ZHAO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ping CHEN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Binbin JI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li SUN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yan WANG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 31, 2010</study_first_submitted>
  <study_first_submitted_qc>January 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2011</study_first_posted>
  <last_update_submitted>August 22, 2011</last_update_submitted>
  <last_update_submitted_qc>August 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mild to moderate asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

